Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties
摘要:
A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.
Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties
摘要:
A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.
1
wherein
R is alkyl, alkenyl, or alkynyl;
R
1
and R
2
are each independently hydrogen alkyl, or aryl; and
Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aroyloxy.
wherein
R is alkyl, alkenyl, or alkynyl;
R1 and R2 are each independently hydrogen alkyl, or aryl; and
Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aroyloxy.
[EN] 3-THIOXO-[1,2,4]-OXADIAZINAN-5-ONE AND THEIR USE AS ANTI-ANTHEROSCLEROTIC AGENTS<br/>[FR] 3-THIOXO-[1,2,4]-OXADIAZINAN-5-ONES ET LEUR UTILISATION COMME AGENTS ANTIATHEROSCLEREUX
申请人:AMERICAN HOME PROD
公开号:WO2002028845A1
公开(公告)日:2002-04-11
This invention relates to 3/thioxo/[1,2,4]-oxadiazinan-5-one derivatives of formula: (I), wherein R is alkyl, alkenyl, or alkynyl; R1 and R2 are each independently hydrogen, alkyl, or aryl; and Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkoxy, dialkylamino, and aroyloxy; that elevate HDL cholesterol concentration, and which may be useful for the treatment of atherosclerotic conditions such as coronary heart disease.